Progress in therapy development for amyotrophic lateral sclerosis

Neurology Research International

Volumn 2012, Issue , 2012, Pages

  Venkova Hristova, Kalina ^a   Christov, Alexandar ^a   Kamaluddin, Zarine ^a   Kobalka, Peter ^a   Hensley, Kenneth ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866182016     PISSN: 20901852     EISSN: 20901860     Source Type: Journal    
DOI: 10.1155/2012/187234     Document Type: Review

References (59)

1. Bento-Abreu A., Van Damme P., Van Den Bosch L., Robberecht W., The neurobiology of amyotrophic lateral sclerosis. European Journal of Neuroscience 2010 31 12 2247 2265 2-s2.0-77953739234 10.1111/j.1460-9568.2010.07260.x
2. Lill C. M., Bertram L., Towards unveiling the genetics of neurodegenerative diseases. Seminars in Neurology 2011 31 5 531 541 10.1055/s-0031-1299791
3. Lill C. M., Abel O., Bertram L., Al-Chalabi A., Keeping up with genetic discoveries in amyotrophic lateral sclerosis: the ALSoD and ALSGene databases. Amyotrophic Lateral Sclerosis 2011 12 4 238 249 2-s2.0-79959763071 10.3109/17482968.2011.584629
4. Lambrechts D., Poesen K., Fernández-Santiago R., Al-Chalabi A., Del Bo R., Van Vught P. W. J., Khan S., Marklund S. L., Brockington A., Van Marion I., Anneser J., Shaw C., Ludolph A. C., Leigh N. P., Comi G. P., Gasser T., Shaw P. J., Morrison K. E., Andersen P. M., Van Den Berg L. H., Thijs V., Siddique T., Robberecht W., Carmeliet P., Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. Journal of Medical Genetics 2009 46 12 840 846 2-s2.0-72749106555 10.1136/jmg.2008.058222
5. Laaksovirta H., Peuralinna T., Schymick J. C., Scholz S. W., Lai S. L., Myllykangas L., Sulkava R., Jansson L., Hernandez D. G., Gibbs J. R., Nalls M. A., Heckerman D., Tienari P. J., Traynor B. J., Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. The Lancet Neurology 2010 9 10 978 985 2-s2.0-77956876046 10.1016/S1474-4422(10)70184-8
6. Shatunov A., Mok K., Newhouse S., Weale M. E., Smith B., Vance C., Johnson L., Veldink J. H., van Es M. A., van den Berg L. H., Robberecht W., Van Damme P., Hardiman O., Farmer A. E., Lewis C. M., Butler A. W., Abel O., Andersen P. M., Fogh I., Silani V., Chiò A., Traynor B. J., Melki J., Meininger V., Landers J. E., McGuffin P., Glass J. D., Pall H., Leigh P. N., Hardy J., Brown R. H. Jr., Powell J. F., Orrell R. W., Morrison K. E., Shaw P. J., Shaw C. E., Al-Chalabi A., Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. The Lancet Neurology 2010 9 10 986 994 2-s2.0-77956877621 10.1016/S1474-4422(10) 70197-6
7. Blauw H. M., Al-Chalabi A., Andersen P. M., van Vught P. W., Diekstra F. P., van Es M. A., Saris C. G., Groen E. J., van Rheenen W., Koppers M., Slot R. V., Strengman E., Estrada K., Rivadeneira F., Hofman A., Uitterlinden A. G., Kiemeney L. A., Vermeulen S. H., Birve A., Waibel S., Meyer T., Cronin S., McLaughlin R. L., Hardiman O., Sapp P. C., Tobin M. D., Wain L. V., Tomik B., Slowik A., Lemmens R., Rujescu D., Schulte C., Gasser T., Brown R. H. Jr., Landers J. E., Robberecht W., Ludolph A. C., Ophoff R. A., Veldink J. H., van den Berg L. H., A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Human Molecular Genetics 2010 19 20 4091 4099 2-s2.0-77957739219 10.1093/hmg/ddq323
8. Gurney M. E., Cutting F. B., Zhai P., Doble A., Taylor C. P., Andrus P. K., Hall E. D., Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Annals of Neurology 1996 39 2 147 157 2-s2.0-0030050727 10.1002/ana.410390203 (Pubitemid 26071564)
9. Gurney M. E., Fleck T. J., Himes C. S., Hall E. D., Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998 50 1 62 66 2-s2.0-0031931578 (Pubitemid 28106020)
10. Hensley K., Mhatre M., Mou S., Pye Q. N., Stewart C., West M., Williamson K. S., On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxidants and Redox Signaling 2006 8 11-12 2075 2087 2-s2.0-33947640544 (Pubitemid 46489632)
11. Scott S., Kranz J. E., Cole J., Lincecum J. M., Thompson K., Kelly N., Bostrom A., Theodoss J., Al-Nakhala B. M., Vieira F. G., Ramasubbu J., Heywood J. A., Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis 2008 9 1 4 15 2-s2.0-39349107014 10.1080/17482960701856300 (Pubitemid 351260367)
12. Rothstein J. D., Martin L. J., Kuncl R. W., Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. The New England Journal of Medicine 1992 326 22 1464 1468 2-s2.0-0026597010
13. Bruijn L. I., Becher M. W., Lee M. K., Anderson K. L., Jenkins N. A., Copeland N. G., Sisodia S. S., Rothstein J. D., Borchelt D. R., Price D. L., Cleveland D. W., ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997 18 2 327 338 2-s2.0-0031051485 10.1016/S0896-6273(00)80272-X (Pubitemid 27111114)
14. Bensimon G., Lacomblez L., Meininger V., A controlled trial of riluzole in amyotrophic lateral sclerosis. The New England Journal of Medicine 1994 330 9 585 591 2-s2.0-0028097839 10.1056/NEJM199403033300901 (Pubitemid 24065791)
15. Miller R. G., Mitchell J. D., Lyon M., Moore D. H., Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2007 1 2-s2.0-34250208597 10.1002/14651858. CD001447.pub2 CD001447 (Pubitemid 351835443)
16. Miller R. G., Moore D., Young L. A., Armon C., Barohn R. J., Bromberg M. B., Bryan W. W., Gelinas D. F., Mendoza M. C., Neville H. E., Parry G. J., Petajan J. H., Ravits J. M., Ringel S. P., Ross M. A., Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996 47 6 1383 1388 2-s2.0-10544254257 (Pubitemid 26422524)
17. Desnuelle C., Dib M., Garrel C., Favier A., A double-blind, placeho-controlled randomized clinical trial of α -tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001 2 1 9 18 2-s2.0-0035007860 10.1080/146608201300079364 (Pubitemid 32472143)
18. De Carvalho M., Pinto S., Costa J., Evangelista T., Ohana B., Pinto A., A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 2010 11 5 456 460 2-s2.0-77956627546 10.3109/17482968.2010.498521
19. Ascherio A., Weisskopf M. G., O'Reilly E. J., Jacobs E. J., McCullough M. L., Calle E. E., Cudkowicz M., Thun M. J., Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals of Neurology 2005 57 1 104 110 2-s2.0-11144244985 10.1002/ana.20316 (Pubitemid 40053321)
20. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., Akaike A., Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. European Journal of Pharmacology 2007 557 2-3 132 140 2-s2.0-33846649595 10.1016/j.ejphar.2006.11. 011 (Pubitemid 46186283)
21. Cudkowicz M., Bozik M. E., Ingersoll E. W., Miller R., Mitsumoto H., Shefner J., Moore D. H., Schoenfeld D., Mather J. L., Archibald D., Sullivan M., Amburgey C., Moritz J., Gribkoff V. K., The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine 2011 17 12 1652 1656 10.1038/nm.2579
22. Pramatarova A., Laganière J., Roussel J., Brisebois K., Rouleau G. A., Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. Journal of Neuroscience 2001 21 10 3369 3374 2-s2.0-0035873076 (Pubitemid 32422802)
23. Clement A. M., Nguyen M. D., Roberts E. A., Garcia M. L., Boillée S., Rule M., McMahon A. P., Doucette W., Siwek D., Ferrante R. J., Brown R. H. Jr., Julien J. P., Goldstein L. S. B., Cleveland D. W., Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003 302 5642 113 117 2-s2.0-0141642203 10.1126/science.1086071 (Pubitemid 37210700)
24. Appel S. H., Smith R. G., Engelhardt J. I., Stefani E., Evidence for autoimmunity in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1993 118 2 169 174 2-s2.0-0027316880 10.1016/0022-510X(93)90106-9 (Pubitemid 23268387)
25. Henkel J. S., Beers D. R., Zhao W., Appel S. H., Microglia in ALS: the good, the bad, and the resting. Journal of Neuroimmune Pharmacology 2009 4 4 389 398 2-s2.0-70449525135 10.1007/s11481-009-9171-5
26. Hall E. D., Oostveen J. A., Gurney M. E., Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998 23 3 249 256 10.1002/(SICI)1098-1136(199807)23:3249:: AID-GLIA7>3.0.CO;2-# (Pubitemid 28259722)
27. Rentzos M., Rombos A., Nikolaou C., Zoga M., Zouvelou V., Dimitrakopoulos A., Alexakis T., Tsoutsou A., Samakovli A., Michalopoulou M., Evdokimidis I., Interleukin-15 and Interleukin-12 are elevated in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. European Neurology 2010 63 5 285 290 2-s2.0-77950933850 10.1159/000287582
28. Kuhle J., Lindberg R. L. P., Regeniter A., Mehling M., Steck A. J., Kappos L., Czaplinski A., Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. European Journal of Neurology 2009 16 6 771 774 2-s2.0-65449167187 10.1111/j.1468-1331.2009.02560.x
29. Mitchell R. M., Freeman W. M., Randazzo W. T., Stephens H. E., Beard J. L., Simmons Z., Connor J. R., A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009 72 1 14 19 2-s2.0-63049130632 10.1212/01.wnl.0000333251.36681.a5
30. Cereda C., Baiocchi C., Bongioanni P., Cova E., Guareschi S., Metelli M. R., Rossi B., Sbalsi I., Cuccia M. C., Ceroni M., TNF and sTNFR1/2 plasma levels in ALS patients. Journal of Neuroimmunology 2008 194 1-2 123 131 2-s2.0-39849105705 10.1016/j.jneuroim.2007.10.028
31. Poloni M., Facchetti D., Mai R., Micheli A., Agnoletti L., Francolini G., Mora G., Camana C., Mazzini L., Bachetti T., Circulating levels of tumour necrosis factor- α and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neuroscience Letters 2000 287 3 211 214 2-s2.0-0034733968 10.1016/S0304-3940(00)01177-0 (Pubitemid 30339386)
32. Hensley K., Fedynyshyn J., Ferrell S., Floyd R. A., Gordon B., Grammas P., Hamdheydari L., Mhatre M., Mou S., Pye Q. N., Stewart C., West M., West S., Williamson K. S., Message and protein-level elevation of tumor necrosis factor α (TNF α) and TNF α -modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiology of Disease 2003 14 1 74 80 2-s2.0-0041833409 10.1016/S0969-9961(03)00087-1 (Pubitemid 37103181)
33. Hensley K., Floyd R. A., Gordon B., Mou S., Pye Q. N., Stewart C., West M., Williamson K., Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry 2002 82 2 365 374 2-s2.0-0036062628 10.1046/j.1471-4159.2002.00968.x (Pubitemid 34774627)
34. Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Niwa J. I., Takeuchi H., Doyu M., Sobue G., Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. Journal of Neurochemistry 2002 80 1 158 167 2-s2.0-0036269810 10.1046/j.0022-3042.2001.00683.x (Pubitemid 34614588)
35. Hensley K., Abdel-Moaty H., Hunter J., Mhatre M., Mhou S., Nguyen K., Potapova T., Pye Q. N., Qi M., Rice H., Stewart C., West M., Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. Journal of Neuroinflammation 2006 3, article 2 2-s2.0-32144439518 10.1186/1742-2094-3-2 (Pubitemid 43205338)
36. Weydt P., Yuen E. C., Ransom B. R., Möller T., Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004 48 2 179 182 2-s2.0-9144230806 10.1002/glia.20062 (Pubitemid 39545949)
37. Kiaei M., Petri S., Kipiani K., Gardian G., Choi D. K., Chen J., Calingasan N. Y., Schafer P., Muller G. W., Stewart C., Hensley K., Beal M. F., Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neuroscience 2006 26 9 2467 2473 2-s2.0-33645642112 10.1523/JNEUROSCI.5253-05.2006 (Pubitemid 44699007)
38. ®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology 2009 220 1 191 197 2-s2.0-70349751944 10.1016/j.expneurol.2009.08.028
39. Stommel E. W., Cohen J. A., Fadul C. E., Cogbill C. H., Graber D. J., Kingman L., MacKenzie T., Channon Smith J. Y., Harris B. T., Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotrophic Lateral Sclerosis 2009 10 5-6 393 404 2-s2.0-70449718115 10.3109/17482960802709416
40. Meyer T., Maier A., Borisow N., Dullinger J. S., Splettstöer G., Ohlraun S., Münch C., Linke P., Thalidomide causes sinus bradycardia in ALS. Journal of Neurology 2008 255 4 587 591 2-s2.0-42549121130 10.1007/s00415-008-0756-3
41. West M., Mhatre M., Ceballos A., Floyd R. A., Grammas P., Gabbita S. P., Hamdheydari L., Mai T., Mou S., Pye Q. N., Stewart C., West S., Williamson K. S., Zemlan F., Hensley K., The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor α activation of microglia and extends survival of G93A-SOD1 transgenic mice. Journal of Neurochemistry 2004 91 1 133 143 2-s2.0-4744362369 10.1111/j.1471-4159.2004. 02700.x (Pubitemid 39314944)
42. Zhu S., Stavrovskaya I. G., Drozda M., Kim B. Y. S., Ona V., Li M., Sarang S., Liu A. S., Hartley D. M., Wu D. C., Guilans S., Ferrante R. J., Przedborski S., Kristal B. S., Friedlander R. M., Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002 417 6884 74 78 2-s2.0-0037007645 10.1038/417074a (Pubitemid 34498818)
43. Drachman D. B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J. D., Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Annals of Neurology 2002 52 6 771 778 2-s2.0-0036895241 10.1002/ana.10374 (Pubitemid 35403187)
44. Cudkowicz M. E., Shefner J. M., Schoenfeld D. A., Zhang H., Andreasson K. I., Rothstein J. D., Drachman D. B., Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology 2006 60 1 22 31 2-s2.0-33745728411 10.1002/ana.20903
45. Gordon P. H., Moore D. H., Miller R. G., Florence J. M., Verheijde J. L., Doorish C., Hilton J. F., Spitalny G. M., MacArthur R. B., Mitsumoto H., Neville H. E., Boylan K., Mozaffar T., Belsh J. M., Ravits J., Bedlack R. S., Graves M. C., McCluskey L. F., Barohn R. J., Tandan R., Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet Neurology 2007 6 12 1045 1053 2-s2.0-36148960127 10.1016/S1474- 4422(07)70270-3 (Pubitemid 350116691)
46. Gowing G., Dequen F., Soucy G., Julien J. P., Absence of tumor necrosis factor- α does not affect motor neuron disease caused by superoxide dismutase 1 mutations. Journal of Neuroscience 2006 26 44 11397 11402 2-s2.0-33750962014 10.1523/JNEUROSCI.0602-06.2006 (Pubitemid 44772169)
47. Caminero A., Comabella M., Montalban X., Tumor necrosis factor alpha (TNF- α), anti-TNF- α and demyelination revisited: an ongoing story. Journal of Neuroimmunology 2011 234 1-2 1 6 2-s2.0-79955646245 10.1016/j.jneuroim.2011.03.004
48. Arteaga S., Andrade-Cetto A., Cárdenas R., Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. Journal of Ethnopharmacology 2005 98 3 231 239 2-s2.0-16244410824 10.1016/j.jep.2005.02.002 (Pubitemid 40461975)
49. Boston-Howes W., Williams E. O., Bogush A., Scolere M., Pasinelli P., Trotti D., Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Experimental Neurology 2008 213 1 229 237 2-s2.0-49349111267 10.1016/j.expneurol.2008.06.010
50. Fischer L. R., Culver D. G., Tennant P., Davis A. A., Wang M., Castellano-Sanchez A., Khan J., Polak M. A., Glass J. D., Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Experimental Neurology 2004 185 2 232 240 2-s2.0-0345742771 10.1016/j.expneurol.2003.10.004 (Pubitemid 38084849)
51. Fischer L. R., Glass J. D., Axonal degeneration in motor neuron disease. Neurodegenerative Diseases 2007 4 6 431 442 2-s2.0-35048855131 10.1159/000107704 (Pubitemid 47557285)
52. Schmidt E. R. E., Pasterkamp R. J., van den Berg L. H., Axon guidance proteins: novel therapeutic targets for ALS? Progress in Neurobiology 2009 88 4 286 301 2-s2.0-67650498361 10.1016/j.pneurobio.2009.05.004
53. Winter F. D., Vo T., Stam F. J., Wisman L. A. B., Bär P. R., Niclou S. P., van Muiswinkel F. L., Verhaagen J., The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Molecular and Cellular Neuroscience 2006 32 1-2 102 117 2-s2.0-33646569146 10.1016/j.mcn.2006.03.002 (Pubitemid 43868100)
54. Hensley K., Venkova K., Christov A., Gunning W., Park J., Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Molecular Neurobiology 2011 43 3 180 191 2-s2.0-79958282898 10.1007/s12035-011-8166-4
55. Duplan L., Bernard N., Casseron W., Dudley K., Thouvenot E., Honnorat J., Rogemond V., De Bovis B., Aebischer P., Marin P., Raoul C., Henderson C. E., Pettmann B., Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death. Journal of Neuroscience 2010 30 2 785 796 2-s2.0-74949142875 10.1523/JNEUROSCI.5411-09.2010
56. Hensley K., Christov A., Kamat S., Zhang X. C., Jackson K. W., Snow S., Post J., Proteomic identification of binding partners for the brain metabolite Lanthionine Ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. Journal of Neuroscience 2010 30 8 2979 2988 2-s2.0-77649092461 10.1523/JNEUROSCI.5247-09.2010
57. Hensley K., Venkova K., Christov A., Emerging biological importance of central nervous system lanthionines. Molecules 2010 15 8 5581 5594 2-s2.0-77956114547 10.3390/molecules15085581
58. Fanara P., Banerjee J., Hueck R. V., Harper M. R., Awada M., Turner H., Husted K. H., Brandt R., Hellerstein M. K., Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. The Journal of Biological Chemistry 2007 282 32 23465 23472 2-s2.0-34548166791 10.1074/jbc.M703434200 (Pubitemid 47311905)
59. Poon H. F., Hensley K., Thongboonkerd V., Merchant M. L., Lynn B. C., Pierce W. M., Klein J. B., Calabrese V., Butterfield D. A., Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic micea model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2005 39 4 453 462 2-s2.0-22544448129 10.1016/j.freeradbiomed.2005.03.030 (Pubitemid 41021644)